Dr. Burrier is a career technology executive with experience in pharmaceutical research, ‘biosupplier’ product development, and biotech services. While working in pharma, he participated and led programs resulting in drugs currently on the market including Zetia, Vytorin, and others.
Point. Act. Thrive.
More precise diagnosis and treatment of autism
Not all children with autism respond to the same treatment because not all children with autism are the same. NeuroPointDX is the world leader in understanding metabolism based differences in children with autism and other neuro-developmental disorders.
NeuroPointDX has demonstrated through its previous three studies of banked blood samples that autism is a spectrum disorder from a metabolism perspective just as it is from a cognitive and behavioral perspective. These differences may allow earlier diagnosis and more precise treatment based on the individual metabolism of the child.